Related references
Note: Only part of the references are listed.Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Leo Yamada et al.
GASTRIC CANCER (2021)
The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes
Shih-Chiang Huang et al.
PLOS ONE (2021)
Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers
Min Zhou et al.
ONCOGENESIS (2021)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
Simon Schallenberg et al.
BMC CANCER (2020)
The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression
Shih-Chiang Huang et al.
HISTOPATHOLOGY (2020)
Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas
Basile Tessier-Cloutier et al.
HISTOPATHOLOGY (2020)
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The SWI/SNF complex in cancer - biology, biomarkers and therapy
Priya Mittal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
SWI/SNF complex differences promote cellular heterogeneity in rhabdoid tumors
Charles G. Eberhart et al.
NEURO-ONCOLOGY (2020)
Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer
Bianca Grosser et al.
CANCERS (2020)
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
Raffaella Soldi et al.
PLOS ONE (2020)
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Hideaki Ogiwara et al.
CANCER CELL (2019)
SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
Tatiana Shorstova et al.
CANCER RESEARCH (2019)
Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors
Amaury Leruste et al.
CANCER CELL (2019)
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Jianfang Liu et al.
CELL (2018)
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer
Jose A. Guerrero-Martinez et al.
SCIENTIFIC REPORTS (2018)
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers
Julien P. N. Papillon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database
Haejin In et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens
Esther Herpel et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2017)
High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications
Sangjeong Ahn et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Clinicopathological Variation of Lauren Classification in Gastric Cancer
Yun-Chi Chen et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2
Abbas Agaimy et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
A protein and mRNA expression-based classification of gastric cancer
Namrata Setia et al.
MODERN PATHOLOGY (2016)
Gastric biomarkers: a global review
Nick Baniak et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Christine Boeger et al.
ONCOTARGET (2016)
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
Martin Kobel et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2016)
SWI/SNF Chromatin Remodeling and Human Malignancies
Julien Masliah-Planchon et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 10 (2015)
Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China
Kai Liu et al.
MEDICINE (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
SMARCB1 (INI1)-negative Rhabdoid Carcinomas of the Gastrointestinal Tract Clinicopathologic and Molecular Study of a Highly Aggressive Variant With Literature Review
Abbas Agaimy et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer
Peter Bronsert et al.
SURGERY (2014)
Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value
Felix Berlth et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition
Eleftherios P. Samartzis et al.
ONCOTARGET (2014)
Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial
Fei Zhou et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
Ilfet Songun et al.
LANCET ONCOLOGY (2010)
Multivariate prognostic study on large gastric cancer
Norio Shiraishi et al.
JOURNAL OF SURGICAL ONCOLOGY (2007)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro
P Ferreira et al.
EXPERIMENTAL CELL RESEARCH (2005)
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
K Becker et al.
CANCER (2003)
Share Paper
